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Summary
Objectives:  This  study  was  carried  out  to  determine  a  point  prevalence  of  drug
resistance  and  extended-spectrum  -lactamase  (ESBL)  among  members  of  the  family
Enterobacteriaceae.
Methods:  Consecutive  clinically  signiﬁcant  non-repetitive  isolates  obtained  from
both  hospitalized  patients  and  outpatients’  samples  were  studied.  The  isolates  were
identiﬁed  using  VITEK  2  while  susceptibility  testing  was  performed  against  16  antibi-
otics  using  the  E-test  strips.  Phenotypic  production  of  ESBL  was  detected  by  E-test
ESBL  method.  Positive  isolates  were  conﬁrmed  by  PCR.
Results:  Of  a  total  of  102  isolates  studied,  43  (42.2%)  were  Escherichia  coli  and
32  (31.4%)  Klebsiella  pneumoniae. These  isolates  demonstrated  remarkable  high
rates  of  resistance  to  the  -lactam  antibiotics,  except  the  carbapenems  and
piperacillin—tazobactam.  Fifty-two  (51%)  were  resistant  to  ≥3  classes  of  drugs  and
29  (28.4%)  to  ≥5  drugs.  Thirty-eight  (37.3%)  were  ESBL  producers.  Of  these,  21
(55.3%)  were  E.  coli  and  12  (31.6%)  K.  pneumoniae. Thus,  the  overall  prevalence  of
ESBL-producing  E.  coli  was  20.6%  and  K.  pneumoniae  11.8%.
Conclusions:  This  study  showed  an  alarmingly  high  prevalence  of  antibiotic  resis-
tance  in  invasive  Enterobacteriaceae  isolates  and  a  high  prevalence  of  ESBL
producers  in  the  study  center.  Antibiotic  stewardship  and  other  preventive  strategies
are  recommended  to  reduc
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Introduction
Antibiotic  resistance  in  clinical  bacterial  isolates
is a  major  problem  in  health  care  settings  and
of grave  public  health  concern  worldwide  [1—3].
There are  several  reasons  for  the  emergence  of
antibiotic  resistant  microorganisms  in  the  clinical
setting.  Empirical  use  of  antibiotics,  particularly
the broad-spectrum  antibiotics,  appears  to  be  a
major factor  driving  the  emergence  of  these  resis-
tant bacteria  [4,5]. The  burden  of  diseases  caused
by these  resistant  bacteria  in  developing  countries
is poorly  documented.
Extended-spectrum  -lactamases  (ESBLs)  capa-
ble of  degrading  the  cephalosporins  and  monobac-
tams are  among  the  most  important  resis-
tance determinants  emerging  in  Enterobacteri-
aceae worldwide  [6]. ESBLs  are  -lactamases
capable of  conferring  bacterial  resistance  to  the
penicillins,  ﬁrst-,  second-,  and  third-generation
cephalosporins  and  aztreonam  by  hydrolysis,
excluding the  cephamycins  and  carbapenems
[7].  These  enzymes  hydrolyze  extended-spectrum
cephalosporins  such  as  ceftazidime  or  cefotaxime
as well  as  monobactams  (aztreonam)  and  are
inhibited  by  -lactamase  inhibitors.  [8]. Although
the prevalence  and  epidemiology  of  ESBLs  have
been well  documented  in  the  developed  countries
there is  paucity  of  data  on  the  prevalence
of antibiotic  resistance  and  ESBL-production  in
Enterobacteriaceae  from  the  developing  countries.
It is conceivable  that  these  resource-limited
countries  could  harbor  new  clones  of  ESBLs  with
propensity to  disseminate  globally.  Therefore,  it  is
of utmost  importance  to  investigate  the  existence
of multidrug-resistant  pathogens  in  the  developing
countries.
This study  was  undertaken  to  determine  the
point-prevalence of  multidrug-resistant  and  ESBL-
producing  members  of  the  family  Enterobacteria-
ceae in  a  state  teaching  hospital  in  Lagos.
Materials and methodology
Bacterial isolates
One  hundred  and  two  consecutive  clinically  sig-
niﬁcant,  non-repetitive  isolates  of  the  family
Enterobacteriaceae  recovered  from  samples  of  102
patients attending  Lagos  State  University  Teach-
ing Hospital  (LASUTH),  over  a  period  of  one  month
(October 2011),  were  studied.  LASUTH  is  a state-
owned  700-bedded  teaching  hospital  with  two
intensive  care  units  (ICUs),  a  dialysis  unit,  and
an oncology  unit.  The  demographic  biodata  of  all
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atients  as  well  as  previous  hospital  admissions  and
ravel history  were  documented.
acterial identiﬁcation
he  bacterial  isolates  were  identiﬁed  using  VITEK-2
ystem  (bioMérieux,  Hazelwood,  MO,  USA).  Iso-
ates with  low  scores  on  VITEK-2  were  subjected
o further  identiﬁcation  on  VITEK  MS  (bioMerieux,
arcy-l’Etoile,  France),  a matrix-assisted  laser
esorption  ionization-time  of  ﬂight  (MALDI-TOF)
ass spectrometry  system  newly  acquired  in  our
uwait laboratory.
usceptibility testing
he  minimum  inhibitory  concentrations  (MICs)  of
6 antibiotics,  amikacin,  ampicillin,  amoxicillin-
lavulanic acid,  aztreonam,  cefepime,  cefotaxime,
eftazidime, cefuroxime,  ciproﬂoxacin,  colistin,
rtapenem,  gentamicin,  imipenem,  meropenem,
iperacillin—tazobactam,  and  tigecycline,  were
etermined  on  Mueller-Hinton  agar  (Oxoid,  Bas-
ngstoke,  UK)  using  E-test  (bioMerieux,  France)
ccording to  manufacturer’s  protocol.  Quality  Con-
rol strain  Escherichia  coli  ATCC  25922  was  included
n each  run  for  media  and  potency  controls.  The
esults  were  interpreted  according  to  the  break-
oints and  criteria  recommended  by  the  Clinical
aboratory Standard  Institute  (CLSI)  [9].
etection of extended-spectrum
-lactamase  (ESBL)
he  E-test  ESBL  method  using  cefotaxime
CT)/cefotaxime  combined  with  clavulanic  acid
CTL) and  ceftazidime  (TZ)/ceftazidime  combined
ith clavulanic  acid  (TZL)  (bioMerieux)  were  used
or the  phenotypic  identiﬁcation  of  the  ESBL-
roducing strains  according  to  the  manufacturer’s
rotocol.
esults
he  ages  of  the  102  patients  ranged  from  5  months
o 90  years  (mean  = 42.4  years);  they  were  52
emales and  50  males.  All  patients  were  Nigerians
f Southwestern  region  origin.  Ninety-four  (92.2%)
ere adults  and  eight  (7.8%)  pediatric  patients.
one gave  history  of  previous  travel  outside  the
ountry or  previous  admission  to  other  hospitals
rior to  the  present  hospital  admission  or  visit.
One isolate  per  patient  was  studied.  Of  the  102
solates,  43  (42.2%)  were  E.  coli,  32  (31.4%)  K.  pneu-
oniae, 11  (10.8%)  Proteus  mirabilis, 10  (9.8%)
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foint-surveillance  of  antibiotic  resistance  in  Entero
nterobacter  cloacae,  4 (3.9%)  Morganella  mor-
anii and  2  (1.9%)  Citrobacter  spp.  Out  of  these,
1 (89.2%)  and  11  (10.8%)  were  from  hospitalized
nd clinic  patients,  respectively.
ocus of infection
ixty-six  (64.7%)  isolates  were  from  urinary  tract
nfections  (UTI);  4  (3.9%)  from  blood  stream  infec-
ions and  20  (19.6%)  from  skin,  soft  tissue  and
urgical site  infections.  Other  6 (5.9%)  isolates  were
rom respiratory  tract  infections;  2 (2%)  ear  infec-
ions and  4  (3.9%)  body  ﬂuids.
ntibiotic susceptibility
he  MICs  of  the  tested  antibiotics  are  shown
n Table  1.  These  results  demonstrated  remark-
ble high  resistance  rates  to  the  -lactam
ntibiotics,  except  the  carbapenems  and
iperacillin—tazobactam.  Colistin,  imipenem,
eropenem  and  tigecycline  demonstrated  excel-
ent activities  against  all  isolates  with  mean
IC90s  of  1.4,  0.88,  0.53  and  1.125  g/ml,  respec-
ively. Amikacin  and  piperacillin—tazobactam  also
howed very  good  activities  with  MIC90s  that  ranged
etween 2—16  and  2—12  g/ml,  respectively.  Four
9.3%)  of  E.  coli  and  4  (12.5%)  K.  pneumoniae
solates were  resistant  to  amoxicillin-clavulanic
cid  (MIC90s  =  4  and  12  g/ml,  respectively);
ostly  at  low-levels  with  over  half  of  the  isolates
equiring only  2  and  0.25  g/ml  for  inhibition.
esistance  rates  of  these  two  important  pathogens
o ampicillin  (MIC90s  of  >  256  g/ml)  were  74.4
nd 100%,  respectively,  and  to  aztreonam  (MIC90s
f 32  and  >256  g/ml)  72.1  and  78.1%,  respec-
ively. These  isolates  were  also  highly  resistant  to
he cephalosporins  including  a  fourth-generation
ephalosporin,  cefepime  with  MIC90s  of  32  and
256 g/ml,  respectively.  The  overall  resistance
ates were  34.9%  and  37.5%,  respectively.  The
IC90s  of  cefotaxime  and  ceftazidime  were  each
256 g/ml,  with  resistance  rates  of  39.5%  and
6.9%, respectively.  The  P.  mirabilis  isolates
xhibited acceptable  susceptibility  ranges  to  all
he antibiotics  tested  except  ampicillin,  aztre-
nam, and  cefuroxime  with  resistance  rates  of
6.4, 27.3,  and  36.4%,  respectively.  Resistance
gainst ceftazidime  was  relatively  high  (18.2%).
igh resistance  rates  were  also  observed  for  E.
loacae  against  ampicillin  (90%),  aztreonam  (80%),
efepime  (70%),  cefotaxime  (80%),  ceftazidime
60%), and  cefuroxime  (100%).  It  is  noteworthy  that
ne isolates  each  of  P.  mirabilis  and  E.  cloacae  had
mipenem  MIC  of  8  g/ml.
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revalence of multidrug-resistant (MDR)
solates
ifty-two  (50.1%)  of  the  isolates  were  multidrug-
esistant (MDR).  MDR  is  deﬁned  in  this  study  as
esistance  to  ≥3  classes  of  antibiotics.  Twenty-eight
53.9%) of  these  were  resistant  to  3—4  classes  of
ntibiotics  and  24  (46.2%)  to  ≥5  classes.  The  most
ommon MDR  isolates  were  E.  coli  and  K.  pneumo-
iae accounting  for  28  (53.9%)  of  52  and  15  (28.9%),
espectively.  Six  (60%)  of  10  E.  cloacae  were  resis-
ant to  more  than  three  classes  of  antibiotics.  The
ther isolates,  P.  mirabilis, M.  morganii  and  Cit-
obacter  freundii,  were  too  small  in  number  for  any
eaningful  analysis.
revalence of ESBL-producing
nterobacteriaceae
able  2 shows  the  point  prevalence  of  ESBL-positive
solates. Out  of the  102  isolates,  38  were  ESBL
roducers, giving  a  point  prevalence  of  37.3%.
f these,  21  (55.3%)  were  E.  coli,  12  (31.6%)  K.
neumoniae, 3  (7.9%)  Proteus  spp.,  1  (2.6%)  M.  mor-
anii and  1 (2.6%)  C.  freundii.  Thus,  the  overall
revalence of  ESBL-producing  E.  coli  was  20.6%,  K.
neumoniae  11.8%,  Proteus  spp.,  2.9%,  M.  morganii
nd P.  mirabilis  1.0%  each.
ESBL-producing  isolates  were  multiply  resistant
o the  cephalosporins  (MIC90s  =  >256  g/ml)
mpicillin (MIC90s  =  >256  g/ml),  aztre-
nam (MIC90s  = >256  g/ml)  and  ciproﬂoxacin
MIC90s  =  >32  g/ml).  They  were  however  suscep-
ible to  amikacin,  colistin,  imipenem,  meropenem
nd tigecycline.
iscussion
ccording  to  a publication  on  behalf  of  the  Infec-
ious Diseases  Society  of  America,  ESBL-positive
. coli  and  K.  pneumoniae  are  two  of  the  organisms
hat are  in  need  of  urgent  new  therapies  [10].  In  our
eport, E.  coli  was  the  commonest  etiological  agent
f nosocomial  and  community-acquired,  compli-
ated,  and  uncomplicated  urinary  tract  infections
UTI)  and  bloodstream  infections  as  in  many  parts
f the  world  [11—13]. Until  recently,  this  organ-
sm used  to  be  the  most  susceptible  member  of  the
amily Enterobacteriaceae.
Our data  demonstrates  very  high  prevalence
ates of  ampicillin-resistant  E.  coli,  E.  cloacae,  and
. morganii. The  carbapenems,  except  ertapenem,
emonstrated excellent  activities  against  all  ESBL-
roducing and  non-ESBL-producing  isolates.  Over
434  M.A.  Raji  et  al.
Table  1  Antimicrobial  susceptibility  pattern  of  the  Enterobacteriaceae  isolates  in  Lagos.
Bacteria/antibiotics  Minimum  inhibitory  concentrations  of  antibiotics
(MICs;  g/ml)
No.  (%)  Resistant
Range  MIC50 MIC90
Escherichia  coli  (43)
Amikacin  0.019—256  2  16  3  (7.0)
Ampicillin  0.002—>256  >256  >256  32  (74.4)
Amoxicillin-clavulanate  0.032—256 2 12  4  (9.3)
Aztreonam  0.064—>256 4 32  31  (72.1)
Cefepime  0.004—>256 0.05 32 15  (34.9)
Cefotaxime  0.094—>256 0.064 >256  17  (39.5)
Ceftazidime  0.004—>256  0.125  >256  12  (27.9)
Cefuroxime  0.05—>256  2  >256  30  (69.8)
Ciproﬂoxacin  0.002—>32  0.012  >32  25  (58.1)
Colistin  0.002—2 0.002  2  1  (2.3)
Ertapenem  0.012—8 0.0125 0.75  7  (16.3)
Gentamicin  0.064—>256 1 16  9  (20.9)
Imipenem  0.094—1.5 0.125 0.75 0 (0)
Meropenem  0.023—0.5 0.094 0.125 0 (0)
Piperacillin—tazobactam 0.008—>256 0.75 12  4  (9.3)
Tigecycline 0.06—2 0.5 1.5 0  (0)
Klebsiella  pneumoniae  (32)
Amikacin  0.002—64  0.5  4  1  (3.1)
Ampicillin  4—>256  >256  >246  31  (96.9)
Amoxicillin-clavulanate  0.064—>256  0.25  16  4  (12.5)
Aztreonam  0.05—>256  0.75  >256  25  (78.1)
Cefepime  0.094—>256  0.5  >256  12  (37.5)
Cefotaxime  0.002—>256  1  >256  15  (46.9)
Ceftazidime  0.002—>256  0.75  32  10  (31.3)
Cefuroxime  0.094—>256  2  >256  17  (53.5)
Ciproﬂoxacin  0.002—>32  0.0125  >32  14  (43.8)
Colistin  0.002—2 0.064  1.5  0  (0)
Ertapenem  0.047—1.5  0.064  0.5  3  (9.4)
Gentamicin  0.125—>256 0.5 >256  13  (40.6)
Imipenem  0.094—1 0.125 0.25 0  (0)
Meropenem  0.023—0.75 0.047 1 0  (0)
Piperacillin—tazobactam 0.025—>256 0.5 8  1  (3.1)
Tigecycline 0.002—1.5 0.125 1  0  (0)
Proteus  mirabilis  (11)
Amikacin  0.064—64  0.75  2  0  (0)
Ampicillin  0.002—>256  1  16  4  (36.4)
Amoxicillin-clavulanate  0.002—4  0.025  4  0  (0)
Aztreonam  0.0125—64 0.25  32  3  (27.3)
Cefepime  0.002—256  0.064  2  1  (9.1)
Cefotaxime  0.004—>256  0.094  2  1  (9.1)
Ceftazidime  0.002—8  0.125  32  2  (18.2)
Cefuroxime  0.002—>256  0.25  128  4  (36.4)
Ciproﬂoxacin  0.002—4  0.025  2  1  (9.1)
Colistin  0.025—1  0.125  1  0  (0)
Ertapenem  0.002—0.25  0.094  0.125  0  (0)
Gentamicin  0.064—4  0.064  2  0  (0)
Imipenem  0.002—8 0.064  1  1  (9.1)
Meropenem  0.002—1.5  0.023  0.5  0  (0)
Piperacillin—tazobactam  0.002—4  0.046  2  0  (0)
Tigecycline  0.064—2  0.125  1  0  (0)
Enterobacter  cloacae  (10)
Amikacin  0.064—64  0.75  4  0  (0)
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Table  1  (Continued)
Bacteria/antibiotics  Minimum  inhibitory  concentrations  of  antibiotics
(MICs;  g/ml)
No.  (%)  Resistant
Range  MIC50 MIC90
Ampicillin  0.002—>256 2 64  9  (90)
Amoxicillin-clavulanate  0.002—32  0.025  128  5  (50)
Aztreonam  0.0125—>256  2  >256  8  (80)
Cefepime  0.002—256  0.5  256  7  (70)
Cefotaxime  0.004—>256  0.75  >256  8  (80)
Ceftazidime  0.002—8 0.125  32  6  (60)
Cefuroxime  0.002—>256  32  >256  10  (100)
Ciproﬂoxacin  0.002—4 0.025  1  1  (10)
Colistin  0.025—1 0.125  1  0  (0)
Ertapenem  0.002—0.5  0.094  0.5  0  (0)
Gentamicin  0.064—16  0.064  16  2  (20)
Imipenem  0.002—8 0.064  1  1  (10)
Meropenem  0.002—1.5  0.023  0.5  0  (0)
Piperacillin—tazobactam  0.002—4 0.046  8  0  (0)
Tigecycline  0.064—2 0.125  1  0  (0)
The others (M. morganii (4) and Citrobacter spp. (2)) are not included in the table.
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i0%  of  the  isolates  were  inhibited  at  very  low
oncentrations of  these  drugs.  This  information
s crucial,  as  these  agents  are  the  recommended
rugs of  choice  for  treating  infections  caused  by
SBL-positive  Enterobacteriaceae  and  show  excel-
ent pharmacodynamic  proﬁling  against  members  of
his family  of  organisms.  Note  worthily,  our  data
hows that  the  activity  of  the  carbapenems  against
SBL-producing  Enterobacteriaceae  is  not  neces-
arily a  class  effect  as  there  are  some  notable
ifferences in activity  among  individual  carbapen-
ms  as  demonstrated  by  the  fact  that  about  16%  of
. coli  and  over  9%  of  K.  pneumoniae  were  resis-
ant to  ertapenem.  This  observation  supports  the
ecommendation  of  the  CLSI  [9]  to  use  ertapenem
s screening  drug  to  detect  resistance  to  carbapen-
ms in  Enterobacteriaceae  in  order  to  avoid  missing
otential  carbapenemase  producers.  However,  it
i
o
m
Table  2  The  prevalence  of  ESBL-producing  isolates  among
Bacteria  (no.  of  isolate)  No.  (%)  of
ESBL-positives
Prop
ESBL
E.  coli  (43) 21  (48.8)  55.3
K.  pneumoniae  (32)  12  (37.5)  31.6
Proteus  mirabilis  (11) 3  (27.3)  7.9
E.  cloacae  (10) 1  (10) 2.6
M.  morganii  (4) 1  (25)  2.6
C.  freundii  (2)  0  (0)  0  (0s  possible  that  this  low-level  resistance  to  only
rtapenem  may  be  due  to  mechanisms  other  than
arbapenemase-mediated  resistance  such  as  the
resence  of  ESBL  and  reduced  permeability  because
f porin  loss.
Antibiotics  with  excellent  activities  against
he Enterobacteriaceae  isolates  were  colistin,
igecycline, amikacin  and,  to  lesser  extent,
iperacillin—tazobactam.  They  remain  alternatives
or treatment  of  serious  infections  caused  by  mem-
ers of  the  family  Enterobacteriaceae.  Colistin
nd tigecycline  appear  to  be  excellent  alternatives
or treating  multidrug-resistant  isolates  including
SBL-positive  strains.  However,  a cautionary  note
s the  limitations  of  the  use  of  these  drugs  such  as
nadequate  serum  level  of  tigecycline  and  toxicity
f colistin.  piperacillin—tazobactam  is not  recom-
ended  for  treating  serious  infections  caused  by
 the  Enterobacteriaceae.
ortion  (%)  of
-positives  (n  =  38)
Overall  prevalence  (%)  of
ESBL-producers  (38/102)
 20.6
 11.8
 2.9
 1.0
 1.0
)  0  (0)
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ESBL-producing  Enterobacteriaceae  but  has  been
recommended  as  a  second  choice  for  treating  non-
bloodstream  E.  coli  infections  [14].
Resistance  of  our  isolates  to  the  cephalosporins
is unacceptably  high,  particularly  resistance  to
cefepime,  cefotaxime,  and  ceftazidime.  These
antimicrobials  are  potent  life-saving  drugs  and  ﬁnd-
ing many  isolates  with  MIC90s  as  high  as  >256  g/ml
is worrisome.  It  is  conceivable  that  high  resistance
rates might  have  been  driven  by  overuse  of  these
drugs, particularly  as  they  are  often  used  as  ﬁrst-
line drugs  in  this  hospital.  Obviously,  this  ﬁnding
makes  these  drugs  unreliable  for  empiric  therapy
in serious  infections  caused  by  E.  coli  and  K.  pneu-
moniae.
The high  resistance  rate  to  ciproﬂoxacin  by
E. coli  and  K.  pneumoniae  is  certainly  one  of
the highest  reported  in  the  literature.  These
rates are  higher  than  those  reported  in  the  MYS-
TIC and  SENTRY  Surveillance  programs  [15]  for
Latin American,  Northern  European  and  South-
ern European  countries,  as  well  as  some  Western
Paciﬁc countries.  This  alarming  phenomenon  of  high
level resistance  to  ciproﬂoxacin  in  Lagos  may  be
explained,  in  part,  by  the  abuse  of  the  drug  by  a
large number  of  physicians  in  the  country.  Many
doctors use  ciproﬂoxacin  to  treat  almost  every
fever with  slightly  raised  ‘‘H’’  antibodies  in  Widal
test that  are  often  misinterpreted  as  typhoid  fever.
These observations,  perhaps,  is a  tip  of  the  ice-
berg. Another  prevalence  study  over  a  longer  period
involving  much  larger  number  of  isolates  is  being
planned  to  conﬁrm  and  extend  our  initial  ﬁndings.
The point  prevalence  (37.3%)  of  ESBL-producing
members  of  the  family  Enterobacteriaceae  in  our
study was  very  high  although  studies  from  other
centers in  the  country  have  found  comparable  and
much higher  prevalence  rates  ranging  from  36.6%
in Benin-City  in  the  south  [16]  to  66.7%  [17]  in
Kano in  the  north.  However,  these  values,  includ-
ing our  ﬁndings,  should  be  compared  with  caution
since  the  methods  employed  in  the  ESBL  detection
in all  of  these  studies  were  dependent  solely  on
phenotypic  analysis.  Nonetheless,  we  believe  that
the important  message  from  our  study  and  others
is the  demonstration  of  high  prevalence  of  ESBL-
producing Enterobacteriaceae  in  our  hospitals.
Conclusion
In conclusion,  our  study  demonstrated  high  preva-
lence rates  of  multidrug-resistant  invasive  isolates
of Enterobacteriaceae,  a  high  number  of  which
were ESBL  producers.  Antibiotic  stewardship  and
other preventive  strategies  are  recommended  to
[M.A.  Raji  et  al.
tem  the  spread  of  antibiotic  resistance  in  Entero-
acteriaceae  in  our  hospital.
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